摘要
目的:考察卡维地洛对动脉硬化大鼠主动脉内皮组织Cx37表达的调节作用,探讨卡维地洛治疗动脉硬化疾病的分子机制。方法:应用逆转录-聚合酶链(RT-PCR)技术测定正常组、动脉硬化组、卡维地洛干预组大鼠主动脉内皮缝隙连接蛋白Cx37 mRNA的表达;应用Western blot法检测不同实验组大鼠主动脉内皮组织Cx37蛋白的表达。结果:与正常对照组相比,动脉硬化组大鼠主动脉内皮Cx37低表达,差异有统计学意义(P<0.05);卡维地洛干预后,随着剂量的增加,大鼠主动脉内皮组织Cx37表达上调,20mg/kg剂量组和30mg/kg剂量组与动脉硬化组相比,有统计学差异(P<0.05)。结论:卡维地洛治疗动脉硬化疾病可能与Cx37表达上调有关。
Objective ：To investigate regulatory effects of carvedilol on Cx37 expression in aortic endothelial tissues of athero 鄄sclerosis rats and explore its molecular mechanism. Methods：Reverse transcription polymerase chain reaction （RT-PCR） and Westernblotting were used to examine the expressions of Cx37 mRNA and Cx37 in the aortic endothelium of the atherosclerosis rats in normalgroup, atherosclerosis group and carvedilol intervention group, respectively. Results： Compared with that of normal control group, theexpression of Cx37 in the aortic endothelium of the atherosclerosis rat was low, and the difference was statistically significant （P〈0. 05）. After the intervention of carvedilol, the expression of Cx37 in the rat aorta was up-regulated with the increase of the carvedilol dose. Conclusions： Carvedilol in the treatment of atherosclerosis may be correlated with its up-regulation of the Cx37 expression.
出处
《中国民康医学》
2014年第2期1-3,6,共4页
Medical Journal of Chinese People’s Health
